Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,067,620 papers from all fields of science
Search
Sign In
Create Free Account
fontolizumab
Known as:
HUZAF
, Immunoglobulin G1, Anti-(Human Interferon Gamma) (Human-Mouse Monoclonal Huzaf Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal Huzaf Light Chain, Dimer
A humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. Fontolizumab binds to and prevents the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Antibodies, Monoclonal, Humanized
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease.
A. Kaser
Best practice & research. Clinical…
2014
Corpus ID: 3277888
Review
2013
Review
2013
[Pharmacology of biologic medications].
M. Marušić
,
S. Mihaljevíc
Acta medica Croatica : casopis Hravatske…
2013
Corpus ID: 24000998
Two major types of inflammatory bowel diseases (IBD) are Crohn's disease (CD) and ulcerative colitis (UC). Insights into their…
Expand
2011
2011
TH1/TH17 profiles in crohn's disease: a cross sectional single centre study in postoperative crohn's disease
A. Murugananthan
,
D. Bernardo
,
+6 authors
H. Al-Hassi
Gut
2011
Corpus ID: 70374041
Introduction Th1 and Th17 pathways are implicated in Crohn's disease (CD). In operative resection samples healthy ileum shows…
Expand
2007
2007
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's diseaseHommes DW, Mikhajlova TL, Stoinov S, et al (Academic…
G. Lichtenstein
2007
Corpus ID: 68784015
2007
2007
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to…
G. Lichtenstein
2007
Corpus ID: 221172580
2006
2006
Intérêt de l’antiinterféron gamma (fontolizumab) dans la maladie de Crohn (MC) modérée à sévère
X. Roblin
Acta Endoscopica
2006
Corpus ID: 21621310
alors appari6s avec des sujets t6moins pour des crit~res d'~ge, de sexe et de dur6e de suivi. Les patients qui avaient pr6sent6…
Expand
Review
2004
Review
2004
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
W. Sandborn
Reviews in gastroenterological disorders
2004
Corpus ID: 25358869
The chimeric monoclonal antibody to tumor necrosis factor (TNF), infliximab, is an effective therapy for Crohn's disease. However…
Expand
2004
2004
Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease
D. Hommes
,
T. Mikhajlova
,
+7 authors
T. Pearce
2004
Corpus ID: 71824060
2004
2004
Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms.
P. C. Bourne
,
S. Terzyan
,
G. Cloud
,
N. F. Landolfi
,
M. Vásquez
,
A. Edmundson
Acta Crystallographica Section D: Biological…
2004
Corpus ID: 24201324
Three-dimensional structures were determined for two crystal forms (orthorhombic P2(1)2(1)2(1) and monoclinic C2) of the Fab from…
Expand
2003
2003
HuZAF, a humanized anti-IFN-γ antibody, inhibits chemokine production by activated T cells and intestinal epithelial cells and blocks chemotaxis of activated CXCR3+lymphocytes
T. Tsao
,
Jianmin Li
,
J. Woo
,
S. Keller
,
C. Klingbeil
,
V. Vexler
2003
Corpus ID: 72084922
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE